- Press Release -

Rockville, Md. The global cell lines market is set to exceed US$ 140 Mn by 2022 on steady growth, according to Fact.MR. Widely used in drug discovery, molecular biology, biochemistry and cell biology, cell lines appeal for their ease of use, cost-effectiveness and ability to deliver pure cells and reproducible results, and rising R&D investment keeps opening new applications.

Basic research is the largest application, cancer cell lines lead by product, and North America is the most lucrative region. Drug discovery and ion channel lines are the fastest-growing pockets.

Applications, Products and End Users

Basic research dominates by application at about 58.7% of revenue, while drug discovery and development grows fastest and forensic testing lags. By product, cancer cell lines hold the largest revenue share and gain ground, while ion channel lines grow fastest at a 3.8% CAGR, followed by GPCR lines. Among end users, academic and research institutes hold the largest share but grow slowly, biopharmaceutical companies hold a high share, and contract research organizations grow at a 3.7% CAGR.

North America is the most lucrative region at a 3.3% CAGR, supported by advanced technology, heavy R&D spending and a deep base of biopharmaceutical companies and research institutes.

Research Investment Drives Demand

The market runs on discovery. As biologics and drug development expand and technology improves, demand for reliable, reproducible cell lines climbs, with cancer and ion channel lines drawing particular interest through the forecast period.

Suppliers and Their Playbook

The field brings together life-science tools and cell engineering companies.

• Abzena Plc., General Electric Company, Sigma-Aldrich Corporation, WuXi AppTec Co., Ltd., Selexis SA, Sartorius AG, Lonza Group Ltd., Corning Incorporated, American Type Culture Collection Inc., and Thermo Fisher Scientific, Inc. are among the key players in the report.

Reading the Market for Decisions

For suppliers, growth favours cancer and ion channel lines and drug-discovery applications. Investors get a small, steadily growing market tied to research budgets. Procurement and lab teams can plan around basic research carrying volume, cancer cell lines leading products, and North America offering the largest opportunity through 2022.

About the Report

Fact.MR's study covers the global cell lines market for the 2017 to 2022 forecast period, with segmentation by product, application, end user and region. It sizes each segment, maps the competitive field, and weighs the research forces shaping demand. Further detail is available in the cell lines market report.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. The firm is known for its syndicated research, custom research and consulting solutions, helping clients make decisions on demand, competition, investment, procurement and future growth.